Most Liquid Drugs Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1XYLO Xylo Technologies
15.2 M
 0.16 
 6.80 
 1.06 
2AMGN Amgen Inc
11.48 B
 0.23 
 1.49 
 0.34 
3CAH Cardinal Health
4.04 B
 0.19 
 1.09 
 0.21 
4HCM HUTCHMED DRC
829.71 M
 0.03 
 3.22 
 0.09 
5TFX Teleflex Incorporated
292.03 M
(0.10)
 3.18 
(0.31)
6EYE National Vision Holdings
258.58 M
 0.06 
 3.00 
 0.19 
7ESPR Esperion Therapeutics
185.84 M
(0.13)
 3.49 
(0.47)
8ALVO Alvotech
128.44 M
(0.04)
 2.16 
(0.09)
9ATEC Alphatec Holdings
107.47 M
 0.04 
 3.46 
 0.15 
10AVDL Avadel Pharmaceuticals PLC
104.12 M
(0.03)
 4.47 
(0.15)
11TMCI Treace Medical Concepts
101.53 M
 0.10 
 3.89 
 0.41 
12BMGL Basel Medical Group
1.74 M
 0.24 
 242.68 
 58.29 
13BDMDW Baird Medical Investment
1.67 M
 0.16 
 68.93 
 11.07 
14TNDM Tandem Diabetes Care
608.73 M
(0.12)
 5.35 
(0.67)
15CTKB Cytek Biosciences
349.89 M
(0.13)
 4.07 
(0.54)
16MASS 908 Devices
212.99 M
 0.14 
 15.71 
 2.22 
17XAIR Beyond Air
72.77 M
(0.08)
 5.94 
(0.50)
18MMSI Merit Medical Systems
51.48 M
 0.05 
 1.55 
 0.07 
19SNDA Sonida Senior Living
32.65 M
 0.04 
 2.33 
 0.08 
20LNSR LENSAR Inc
25.2 M
 0.23 
 5.97 
 1.39 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).